In patients with melanoma or non-small cell lung cancer, consuming high levels of the artificial sweetener sucralose ...

A research team has developed a technology that distinguishes lung cancer gene mutations solely by measuring the "stiffness" of exosomes—tiny particles released from cancer cells in the ...

While the liquid biopsy technology continues to evolve for lung cancer management, researchers are working toward further ...

The American College of Chest Physicians (CHEST) recently released a new clinical guideline on the management of patients ...

In December 2024, the FDA approved Ensacove as a first-line treatment for non-small-cell lung cancer (NSCLC) in certain adults. NSCLC is the most common type of lung cancer.

Non-small cell lung cancer (NSCLC) develops in lung tissues, but when it's metastatic, it has spread to distant areas of the ...

Imdelltra received accelerated approval from the U.S. Food and Drug Administration in May 2024 for patients with extensive-stage small cell lung cancer with disease progression on or after ...

Topline data were announced from a phase 3 trial evaluating tarlatamab-dlle (Imdelltra ®) for the treatment of small cell lung cancer (SCLC) in patients who progressed on or after a single line ...

The drug is being developed for the treatment of small cell lung cancer and neuroendocrine carcinoma, including neuroendocrine prostate cancer. The multi-center, first-in-human, open-label, phase 2/3 ...